Halozyme Therapeutics Inc [HALO] stock prices are up 0.29% to $53.45 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HALO shares have gain 6.41% over the last week, with a monthly amount drifted -6.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on May 14, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $62 for it. Previously, Leerink Partners downgraded its rating to Underperform on May 13, 2025, and kept the price target unchanged to $47. On October 07, 2024, downgrade downgraded it’s rating to Equal Weight and revised its price target to $62 on the stock. JP Morgan downgraded its rating to a Neutral and increased its price target to $57 on September 19, 2024. Piper Sandler downgraded its rating to a Neutral and raised its price target to $51 on June 07, 2024. TD Cowen started tracking with a Outperform rating for this stock on February 29, 2024, and assigned it a price target of $54. In a note dated July 24, 2023, H.C. Wainwright initiated an Buy rating and provided a target price of $61 on this stock.
The stock price of Halozyme Therapeutics Inc [HALO] has been fluctuating between $42.01 and $70.50 over the past year. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $53.45 at the most recent close of the market. An investor can expect a potential return of 16.0% based on the average HALO price forecast.
Analyzing the HALO fundamentals
The Halozyme Therapeutics Inc [NASDAQ:HALO] reported sales of 1.08B for trailing twelve months, representing a surge of 35.22%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.55%, Pretax Profit Margin comes in at 0.56%, and Net Profit Margin reading is 0.45%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 1.22 and Total Capital is 0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Halozyme Therapeutics Inc [NASDAQ:HALO]’s Current Ratio is 8.39. In addition, the Quick Ratio stands at 7.30 and the Cash Ratio stands at 1.17. Considering the valuation of this stock, the price to sales ratio is 6.07, the price to book ratio is 13.65 and price to earnings (TTM) ratio is 14.18.
Transactions by insiders
Recent insider trading involved Henderson Jeffrey William, Director, that happened on Apr 28 ’25 when 4497.0 shares were sold. Director, Henderson Jeffrey William completed a deal on Apr 01 ’25 to sell 503.0 shares. Meanwhile, Director Henderson Jeffrey William sold 5000.0 shares on Mar 03 ’25.
